CRA International (CRAI) Lands BriaCell Engagement, Is The Stock Still Undervalued?
CRA International (CRAI) is back in focus after BriaCell Therapeutics engaged the firm to support commercial strategy, market access evaluation and brand planning for Bria-IMT in metastatic breast cancer.
See our latest analysis for CRA International.
CRA International’s latest BriaCell engagement comes as the stock trades at US$160.64, with a 7 day share price return of 9.44% but a year to date share price decline of 19.89%. The 3 year total shareholder return of 63.54% points to stronger longer term performance.
If this kind of specialist consulting work has your attention, it could be a good moment to broaden your search and check out 18 top founder-led companies
CRA International’s share price has just bounced, yet it still sits well below both analyst targets and some intrinsic value estimates. How wide is that gap in practical terms, and where does fair value really look to sit?
Most Popular Narrative: 36.4% Undervalued
The most followed CRA International narrative places fair value at $252.50, well above the last close of $160.64, framing a sizeable valuation gap for investors to interrogate.
The analysts have a consensus price target of $252.5 for CRA International based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $890.9 million, earnings will come to $74.0 million, and it would be trading on a PE ratio of 26.2x, assuming you use a discount rate of 7.9%.
Want to know what needs to happen for CRA International to justify that kind of fair value gap? The narrative leans on steady revenue expansion, higher profit margins, and a richer earnings multiple than the sector typically commands. Curious which pieces of that trio carry the most weight in the model?
Result: Fair Value of $252.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, CRA International’s reliance on robust M&A and antitrust work, alongside ongoing share buybacks funded with net debt, could pressure both revenue resilience and financial flexibility if conditions shift.
Find out about the key risks to this CRA International narrative.
Next Steps
With CRA International presenting both concerns and reasons for optimism, it makes sense to move quickly and pressure test the numbers yourself. To weigh those issues and potential upsides side by side, start with the 2 key rewards and 3 important warning signs.
Looking for more CRA International style investment ideas?
If CRA International has sharpened your focus, do not stop here. Use the Simply Wall St Screener to uncover other opportunities that could strengthen your portfolio.
- Target potential bargains by scanning companies that combine robust fundamentals with appealing valuations using the 44 high quality undervalued stocks.
- Strengthen your search for resilience by filtering for companies assessed as having sturdier finances through the solid balance sheet and fundamentals stocks screener (47 results).
- Spot potential future standouts early by reviewing the screener containing 19 high quality undiscovered gems before others catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com